meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
new pathology
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus pomalidomide and dexamethasone
versus all
vs Immunosuppressant
vs pomalidomide based treatment
vs pomalidomide and dexamethasone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus pomalidomide and dexamethasone
title
pomalidomide and dexamethasone
title
KEYNOTE-183, 2019 NCT02576977 multiple myeloma - 2nd line (L2) 125/124
Pathology:
multiple myeloma - 2nd line (L2);
multiple myeloma - 2nd line (L2)
KEYNOTE-183, 2019
pembrolizumab plus pomalidomide and dexamethasone
1
T1
pomalidomide and dexamethasone
0
T0